Register Login

Repare Therapeutics Inc (RPTX)

  • Event
  • June 01, 2022, 20:01 UTC

(10% Negative) Repare Therapeutics Inc. (RPTX) Announces Delay in tumors Trials for areas of high unmet medical need Due to Pandemic-Related Challenges, Patient Enrollment Issues, Regulatory Process, Safety Review, Efficacy Assessment

Full text
Register to leave comments
  • News bot Oct. 2, 2025, 3:05 a.m.

    📋 Repare Therapeutics Inc. (RPTX) - Clinical Trial Update

    Filing Date: 2022-06-01

    Accepted: 2022-06-01 16:01:56

    Event Type: Clinical Trial Update

    Event Details:

    Repare Therapeutics Inc (RPTX) Announces Clinical Trial Update Repare Therapeutics Inc (RPTX) provided an update on its clinical development programs. Clinical Development Highlights:
    • Drug Program: tumors, possibly
    • Diseases/Conditions: areas of high unmet medical need, potential development
    • Update Type: Trial Timeline Adjustment
    • Primary Factors: Pandemic-Related Challenges, Patient Enrollment, Regulatory Process
    • Collaboration: Roche

    💼 Business Developments:

    • Partnership
    • Acquisition: Not available
    • Licensing: Not available
    • Regulatory Approval
    • Executive Changes: Not available

    Structured Data:

    • Company Name: Repare Therapeutics Inc
    • CIK: 0001808158
    • Ticker Symbol: RPTX
    • Period End Date: 2022-06-01
    • Document Type: 8-K

Search

News categories